In ovarian cancer, ALKBH5 activates the EGFR-PIK3CA-AKT-mTOR signaling pathway, enhances the stability of BCL-2 mRNA, and promotes the interaction between BCL-2 and Beclin 1. Here, ALKBH5 is linked to ovarian carcinoma.